Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p37
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 37/191)
Character Range: 9882474–9893448

- Streamlined Authority Code 5526
                                                                                                                                                                                                                               Initial Treatment
                                                                                                                                                                                                                               Patient must have RAS wild-type metastatic colorectal cancer; AND
                                                                                                                                                                                                                               Patient must have a WHO performance status of 0 or 1; AND
                                                                                                                                                                                                                               The condition must be previously untreated; AND
                                                                                                                                                                                                                               The treatment must be in combination with first-line chemotherapy; AND
                                                                                                                                                                                                                               The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition.
                                                                                                                                                                                                                               Patients who have progressive disease on cetuximab are not eligible to receive PBS-subsidised panitumumab.
                                                                                                                                                                                                                               Patients who have developed intolerance to cetuximab of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised panitumumab.
C5529               P5529          CN5529           Omeprazole                                                                                                                                                                 Zollinger-Ellison syndrome

                                                    Pantoprazole

C5530               P5530          CN5530           Lanthanum                                                                                                                                                                  Hyperphosphataemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Compliance with Authority Required procedures - Streamlined Authority Code 5530
                                                                                                                                                                                                                               Initiation and stabilisation
                                                    Sevelamer                                                                                                                                                                  The condition must not be adequately controlled by calcium; AND
                                                                                                                                                                                                                               Patient must have a serum phosphate of greater than 1.6 mmol per L at the commencement of therapy; or
                                                    Sucroferric oxyhydroxide                                                                                                                                                   The condition must be where a serum calcium times phosphate product is greater than 4 at the commencement of therapy; AND
                                                                                                                                                                                                                               The treatment must not be used in combination with any other non-calcium phosphate binding agents; AND
                                                                                                                                                                                                                               Patient must be undergoing dialysis for chronic kidney disease.
C5532               P5532          CN5532           Cyproterone                                                                                                                                                                Moderate to severe androgenisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Compliance with Authority Required procedures - Streamlined Authority Code 5532
                                                                                                                                                                                                                               The condition must not be indicated by acne alone, as this is not a sufficient indication of androgenisation;
                                                                                                                                                                                                                               Patient must be female;
                                                                                                                                                                                                                               Patient must not be pregnant.
C5533               P5533          CN5533           Amino acid formula with fat, carbohydrate without phenylalanine and tyrosine                                                                                               Tyrosinaemia

                                                    Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine and tyrosine

                                                    Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine and tyrosine, and supplemented with docosahexaenoic acid

                                                    Amino acid formula with vitamins and minerals without phenylalanine and tyrosine

                                                    Amino acid formula with vitamins and minerals, without phenylalanine, tyrosine and supplemented with arachidonic acid and docosahexaenoic acid

                                                    Glycomacropeptide and essential amino acid formula with vitamins, minerals, and low in tyrosine and phenylalanine

                                                    Glycomacropeptide and essential amino acids with vitamins and minerals

                                                    Phenylalanine with carbohydrate

C5534               P5534          CN5534           Amino acid formula with fat, carbohydrate without methionine                                                                                                               Pyridoxine non-responsive homocystinuria

                                                    Amino acid formula with fat, carbohydrate, vitamins, minerals, and trace elements, without methionine and supplemented with docosahexaenoic acid

                                                    Amino acid formula with vitamins and minerals without methionine

                                                    Amino acid formula with vitamins and minerals without methionine and supplemented with arachidonic acid and docosahexaenoic acid

C5535               P5535          CN5535           Ciprofloxacin                                                                                                                                                              Chronic suppurative otitis media                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Compliance with Authority Required procedures
                                                                                                                                                                                                                               Patient must be less than 18 years of age;
                                                                                                                                                                                                                               Patient must have a grommet in situ.
C5540               P5540          CN5540           Mycobacterium bovis (Bacillus Calmette and Guerin (BCG)) Danish 1331 strain                                                                                                Primary and relapsing superficial urothelial